MYCN and small cell lung carcinoma: In adult cancers, amplification of MYCN is present in 40% of neuroendocrine prostate cancers and 5% of prostate adenocarcinomas (32), 15%-20% of small-cell lung cancers (33, 34) and 17.5% of basal cell carcinomas (35).